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Abstract
In this nationwide, population-based study, we assessed 10-year relative survival among 225,305 patients with
ten early-stage cancers diagnosed in the Netherlands during 2004–2015. This study aimed to ascertain which
early-stage cancer is associated with minimal or no excess mortality and likely to be diagnosed in individuals
who are otherwise more healthy or health-conscious than their counterparts in the general population. Ten-
year relative survival marginally exceeded 100% in patients with early-stage prostate cancer, while it was close
to 100% for patients with ductal carcinoma in situ (DCIS) and stage I cancers of the breast, skin (melanoma),
testis, and thyroid. In contrast, patients with early-stage oral/pharyngeal, bladder, lung, and pancreatic cancers
experienced considerable excess mortality, reflected by a 10-year relative survival of 74.9%, 69.4%, 45.5%, and
33.9%, respectively. Collectively, the life expectancy of patients with DCIS and early-stage cancers of the
prostate, breast, skin (melanoma), testis, and thyroid parallels the expected survival of an age-, sex-, and
calendar year-matched group from the general population. Our study findings add to the controversy
surrounding overdiagnosis of particular early-stage cancers that are generally not destined to metastasis or
cause excess mortality.
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To the Editor,
Recently, Marcadis et al. performed a comprehen-
sive analysis of relative survival in 281,970 patients
with ten early-stage cancers using data from the
Surveillance, Epidemiology, and End Results Pro-
gram—a study that was hitherto lacking in contem-
porary literature [1]. They identified five early-stage
cancers—i.e., ductal carcinoma in situ (DCIS) and
early-stage cancers of the prostate, skin (melanoma),
thyroid, and breast—with 10-year relative survival ex-
ceeding 100%, suggesting that patients with these
early-stage cancers have greater longevity compared
to an equivalent group from the general population.
This finding favors the premise that these early-stage
cancers—which presumably lack metastatic potential
and have limited lethal consequences—are generally
detected incidentally or via screening in individuals
who are otherwise more healthy or health-conscious
than their counterparts in the general population [2].
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This phenomenon can to some extent be referred to
as overdiagnosis [3].
At present, it is unknown whether the findings of
Marcadis et al. extend to populations outside the
USA. Therefore, we sought to complement their find-
ings by delineating the relative survival of patients
with early-stage cancers in the Netherlands.
We selected patients with ten early-stage cancers diag-
nosed during 2004–2015 from the nationwide
Netherlands Cancer Registry (NCR). The selection of
early-stage cancers and the study period is congruent
with the selection as per Marcadis et al. [1]. The Privacy
Review Board of the NCR approved the use of anonym-
ous data for this study.
The primary endpoint was 10-year relative survival,
defined as the time from diagnosis until death, emi-
gration, or end of follow-up (February 1, 2019),
whichever occurred first. Relative survival was calcu-
lated according to the cohort methodology to esti-
mate disease-specific survival [4]. Relative survival is
the ratio of the observed survival of patients to the
expected survival of an age-, sex-, and calendar year-
matched group from the general population. Expected
survival was calculated as per the Ederer II method-
ology using Dutch life tables, stratified by age, sex,
and calendar year. All analyses were performed using
STATA (version 14.2, StataCorp).
Our analytical cohort included 225,305 patients with
ten early-stage cancers diagnosed in the Netherlands
during 2004–2015 (Fig. 1). Ten-year relative survival
marginally exceeded 100% in patients with early-stage
prostate cancer (101.4%; 95% CI, 100.7–102.0%), while
it was close to 100% for patients with DCIS and stage
I cancers of the skin (melanoma), testis, and thyroid
(Fig. 2). Patients with stage I breast cancer experi-
enced minimal excess mortality, while patients with
early-stage oral/pharyngeal, bladder, lung, and pancre-
atic cancers experienced considerable excess mortality
(Fig. 2).
In this nationwide, population-based study, the life
expectancy of patients with early-stage prostate cancer
slightly surpassed that of an equivalent group from
the general population. This finding is congruent—al-
beit to a lesser extent—with those observed in the
USA (Fig. 2) [1]. Besides, relative survival exceeded
100% among US patients with DCIS and early-stage
cancers of the thyroid, skin (melanoma), and breast.
In the Netherlands, however, relative survival in these
patients ranges between 96% and 100%, which closely
mirrors the disease-specific survival in the USA [1]
Hence, relative survival in these early-stage cancers is
likely to be overestimated in the USA. Seemingly,
there is an overrepresentation of health-conscious in-
dividuals (e.g., those from higher socioeconomic
groups or with adequate insurance coverage) in the
US patient population with early-stage cancers. More-
over, these patients have a higher life expectancy than
their counterparts in the general population and per-
haps more diligently participate in periodic health ex-
aminations and cancer screening programs (i.e.,
healthy-user bias)—all of which may render a cancer
diagnosis earlier in the disease course (i.e., lead-time
bias) [2, 5, 6]. Sex- and treatment-related factors
might also be at play with regard to disparities in
relative survival between the Netherlands and the
USA. The effect of sex and variation in treatment on
relative survival could not be evaluated since informa-
tion on sex and therapy was not analyzed in the
study by Marcadis et al. [1].
Collectively, it can be reasoned that the magnitude
of potential cancer overdiagnosis and health inequal-
ities regarding access to screening, diagnosis, treat-
ment, and follow-up services is less extensive in the
Netherlands than in the USA, because all Dutch resi-
dents have equal access to health care services—re-
gardless of their socioeconomic position and race,
ethnicity, and gender. This topic provides an avenue
for future research to close the gap in cancer survival
between the Netherlands and the USA. This research
requires detailed analyses on the drivers of survival
Fig. 1. Distribution of early-stage cancers in the Netherlands
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disparities in early-stage cancers between the
Netherlands and the USA.
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Fig. 2. Relative survival of early-stage cancers in the Netherlands compared to the USA. The emerald green bar depicts the 10-year relative
survival rate in the USA as per Marcadis et al. [1], the orange bar depicts the 10-year relative survival rate in the Netherlands, and the gray error
bar depicts the 95% confidence intervals for the 10-year relative survival rate. The table presents the ten-year relative survival (RS) rates for the ten
early-stage cancers according to country. Bold estimates in the table indicate 10-year relative survival rates exceeding 100%. Relative survival is a
popular net measure to quantify cancer patient survival with cancer registry data, which measures the survival of cancer patients relative to the
expected survival of a comparable group from the general population [4]. Its popularity emanates from the fact that it does not depend on the
cause of death, which is often unavailable or unreliable in cancer registry data. In view of this, disease-specific survival—which relies on the
accurate classification of the cause of death—might be miscalculated with cancer registry data. Therefore, relative survival is generally considered
a proper measure to estimate disease-specific survival and to inform cancer patients about their outlook relative to an equivalent group from the
general population. Our study population exclusively includes patients with one primary tumor that has been pathologically confirmed. The stage
of the cancer was determined using the Tumor-Node-Metastasis (TNM) classification prevailing at the time of diagnosis. Also, the Gleason scoring
system was used to grade prostate cancer. The location and histology of the tumor are registered in the Netherlands Cancer Registry according
to the Third Edition of the International Classification of Diseases for Oncology (ICD-O-3)
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